Mirum Pharmaceuticals, Inc. Stock Analysis & AI Score
Mirum Pharmaceuticals, Inc. (MIRM) has an ST Score of 51.5 (C+), driven by its Momentum (B) and held back by its Profitability (C-). Analysts rate it Buy with a $140.20 price target (+56.9% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Mirum Pharmaceuticals, Inc. (MIRM) has an ST Score of 51.5 (C+), driven by its Momentum (B) and held back by its Profitability (C-). Analysts rate it Buy with a $140.20 price target (+56.9% upside).
- Strongest
- MomentumB
- Weakest
- ProfitabilityC-
All factor grades
- MomentumB
- GrowthB
- ForecastB
- ValuationB-
- Financial StrengthC+
- ProfitabilityC-
- Piotroski3/9
Contact
MIRM stock: frequently asked questions
What is MIRM's ST Score?
Mirum Pharmaceuticals, Inc. (MIRM) has an ST Score of 51.5 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is MIRM a buy, hold, or sell?
Analysts rate MIRM a Buy, with a price target of $140.20 (+56.9% vs the current price). Our ST Score grades it C+ (51.5/100). The ST Score is a data-driven signal, not a recommendation.
What are MIRM's factor grades?
Valuation B-, Profitability C-, Financial Strength C+, Momentum B, Growth B, Forecast B.
What is MIRM's valuation grade?
Mirum Pharmaceuticals, Inc. (MIRM) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is MIRM's growth grade?
Mirum Pharmaceuticals, Inc. (MIRM) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is MIRM's profitability grade?
Mirum Pharmaceuticals, Inc. (MIRM) earns a profitability grade of C-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is MIRM's financial strength grade?
Mirum Pharmaceuticals, Inc. (MIRM) earns a financial strength grade of C+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for MIRM?
The average analyst price target for Mirum Pharmaceuticals, Inc. (MIRM) is $140.20 from 18 analysts, which is +56.9% versus the recent price of $89.36.
What is MIRM's Piotroski score?
Mirum Pharmaceuticals, Inc. (MIRM) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.